HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.

AbstractBACKGROUND:
Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed of proteinaceous fibrils and extracellular matrix proteins found in all patients with AL and in ~10-30% of patients who presented with MM. Amyloid deposits systemically in multiple organs and tissues leading to dysfunction and ultimately death. The overall survival of patients with amyloidosis is worse than for those with early stage MM.
METHODS AND FINDINGS:
We have developed a sensitive binding assay quantifying the recruitment of full length, patient-derived LC proteins by synthetic amyloid fibrils, as a method for studying their amyloidogenic potential. In a survey of eight urinary LC, both AL and MM-associated proteins were recruited by synthetic amyloid fibrils; however, AL-associated LC bound significantly more efficiently (p < 0.05) than did MM LCs. The LC proteins used in this study were isolated from urine and presumed to represent a surrogate of serum free light chains.
CONCLUSION:
The binding of LC to synthetic fibrils in this assay accurately differentiated LC with amyloidogenic propensity from MM LC that were not associated with clinical amyloid disease. Notably, the LC from a MM patient who subsequently developed amyloid behaved as an AL-associated protein in the assay, indicating the possibility for identifying MM patients at risk for developing amyloidosis based on the light chain recruitment efficacy. With this information, at risk patients can be monitored more closely for the development of amyloidosis, allowing timely administration of novel, amyloid-directed immunotherapies-this approach may improve the prognosis for these patients.
AuthorsEmily B Martin, Angela Williams, Craig Wooliver, R Eric Heidel, Sarah Adams, John Dunlap, Marina Ramirez-Alvarado, Luis M Blancas-Mejia, Ronald H Lands, Stephen J Kennel, Jonathan S Wall
JournalPloS one (PLoS One) Vol. 12 Issue 3 Pg. e0174152 ( 2017) ISSN: 1932-6203 [Electronic] United States
PMID28350808 (Publication Type: Journal Article)
Chemical References
  • Amyloid
  • Amyloidogenic Proteins
  • Immunoglobulin Light Chains
  • Urea
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amyloid (immunology, metabolism, ultrastructure)
  • Amyloidogenic Proteins (immunology, metabolism)
  • Amyloidosis (immunology, metabolism)
  • Blotting, Western
  • Electrophoresis, Polyacrylamide Gel
  • Female
  • Humans
  • Immunoglobulin Light Chains (chemistry, immunology, metabolism)
  • Immunoglobulin Light-chain Amyloidosis
  • Male
  • Microscopy, Immunoelectron
  • Middle Aged
  • Multiple Myeloma (immunology, metabolism)
  • Prognosis
  • Protein Binding
  • Protein Multimerization (drug effects)
  • Surface Plasmon Resonance
  • Thermodynamics
  • Urea (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: